In conclusion, the role of KMO in the treatment of neurological diseases is mainly influenced by its directly controlled QUIN and indirectly controlled KYNA; thus, the study of their relationship may be a direction for future treatment and KMO inhibitors may be the sustained therapeutic potential in nervous system diseases (Pellicciari et al., 2003; Richter & Hamann, 2003) and prefer the neuroprotective function (Amori, Guidetti, Pellicciari, Kajii, & Schwarcz, 2009). Here, KMO is linked to nervous system disorder.